A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer

Condition:   Prostatic Neoplasms, Castration-Resistant Interventions:   Drug: JNJ-809;   Drug: Apalutamide Sponsor:   Janssen Research & Development, LLC Not yet recruiting - verified September 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials